Boulevard Bio launches with $65 million from Deerfield and world-class founders

Boulevard Bio announced its emergence from stealth with $65 million from founding investor Deerfield Management and early Phase 1 healthy volunteer data for lead candidate BLVD101, a dual BAFF/APRIL-targeting bispecific antibody, supporting a 12-week (quarterly) dosing interval in IgA nephropathy (I...